Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transfusion Reactions

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    77 result(s) found for: Transfusion Reactions. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2012-002920-33 Sponsor Protocol Number: CLI00076 Start Date*: 2012-12-10
    Sponsor Name:CERUS CORPORATION
    Full Title: A Randomized Controlled Study to Evaluate Efficacy and Safety of S-303 Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion
    Medical condition: Subjects with Thalassemia Major Requiring Chronic RBC Transfusion
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002622-39 Sponsor Protocol Number: PEDFOI Start Date*: 2015-11-18
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Experimental Study Protocol on Treatment with plasma transfusions in Patients affected by type VI Osteogenesis Imperfecta
    Medical condition: type VI Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000936-24 Sponsor Protocol Number: SHINE-TRAUMA Start Date*: 2019-05-02
    Sponsor Name:Section for Transfusion Medicine, Capital Region Blood Bank, Copenhagen University Hospital
    Full Title: Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in trauma patients with haemorrhagic shock induced endotheliopathy – a multicentre randomized, placebo-controlled, blinded, inv...
    Medical condition: Shock-induced endotheliopathy in trauma patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10044528 Traumatic injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2011-003173-28 Sponsor Protocol Number: 11112 Start Date*: 2012-06-13
    Sponsor Name:Helsinki University Hospital
    Full Title: Volume replacement therapy in cardiac surgery: effect on renal function.
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001867-22 Sponsor Protocol Number: PRETIC Start Date*: 2018-09-27
    Sponsor Name:Banc de Sang i teixits
    Full Title: TRANSFUSION OF RED BLOOD CELLS, TRANEXAMIC ACID AND FIBRINOGEN CONCENTRATE FOR SEVERE TRAUMA HEMORRHAGE AT PRE-HOSPITAL PHASE OF CARE. A PILOT TRIAL.
    Medical condition: TREATMENT OF SEVERE TRAUMA HEMORRHAGE AT PRE-HOSPITAL PHASE OF CARE.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10019524 Hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003978-16 Sponsor Protocol Number: PRooF-iTH Start Date*: 2015-01-22
    Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank
    Full Title: Pilot Randomized trial of Fibrinogen in Trauma Haemorrhage (PRooF-iTH).
    Medical condition: Trauma patients with ongoing haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10005103 Bleeding LLT
    17.1 100000004863 10044461 Trauma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001296-33 Sponsor Protocol Number: COMBAT-COVID-19 Start Date*: 2020-05-06
    Sponsor Name:Section for Transfusion Medicine, Capital Region Blood bank, Copenhagen University Hospital
    Full Title: Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-ini...
    Medical condition: COVID-19 induced respiratory failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10038696 Respiratory failure (excl neonatal) LLT
    20.0 100000004862 10040050 Sepsis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-002341-20 Sponsor Protocol Number: PLAF1003 Start Date*: 2008-07-10
    Sponsor Name:Queen Charlotte's and Chelsea Hospital
    Full Title: Randomized controlled trial comparing the effect of carbetocin vs syntocinon and ergometrine on postpartum haemorrhage in patients undergoing elective caesarean section
    Medical condition: Clinical efficacy comparing ( 2 drugs) carbetocin Vs syntocinon and ergometrine
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003416-38 Sponsor Protocol Number: TMP-0916_02 Start Date*: 2018-04-05
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
    Full Title: Randomised, open lable, active controlled clinical trial to demonstrate safety and efficacy of an i.v. administration of Polyglucoferron compared to i.v. Ferric Carboxymaltose and oral iron substit...
    Medical condition: preoperative iron deficiency anaemia in patients with planned elective non-cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001829-11 Sponsor Protocol Number: UoL001337 Start Date*: 2018-10-04
    Sponsor Name:University of Liverpool
    Full Title: The Carboprost or Oxytocin Postpartum haemorrhage Effectiveness Study. Carboprost vs Oxytocin as the First Line Treatment of Primary Postpartum Haemorrhage; A phase IV, double-blind, double-dummy, ...
    Medical condition: Primary postpartum haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004868 10055323 Postpartum hemorrhage (primary) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-003235-30 Sponsor Protocol Number: H9H-MC-JBAV Start Date*: 2014-02-10
    Sponsor Name:Eli Lilly and Company
    Full Title: Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes
    Medical condition: Myelodysplastic Syndromes
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005486-14 Sponsor Protocol Number: EPIC-19 Start Date*: 2021-01-11
    Sponsor Name:Wroclaw Medical University
    Full Title: Using of convalescent plasma in the treatment of COVID-19 patients with metabolomic and laboratory evaluation of the progress of plasma therapy
    Medical condition: Covid-19 (Coronavirus Disease 2019) – acute infectious disease of the respiratory system caused by SARS-CoV-2 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000568-32 Sponsor Protocol Number: CLLTX1 Start Date*: 2017-11-07
    Sponsor Name:Universität Köln
    Full Title: Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation
    Medical condition: Patients with poor risk CLL and Richter`s transformation requiring an allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004931-21 Sponsor Protocol Number: BO42162 Start Date*: 2020-10-26
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTUR...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing) DE (Ongoing) HU (Completed) FR (Ongoing) PL (Ongoing) GR (Completed) PT (Ongoing) BE (Ongoing) IE (Prematurely Ended) EE (Completed) LT (Ongoing) IT (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003122-28 Sponsor Protocol Number: ArgLepi-2006 Start Date*: 2008-12-19
    Sponsor Name:Heinrich-Heine-Universität Düsseldorf
    Full Title: Argatroban versus Lepirudin in Critically Ill Patients
    Medical condition: Critically ill patients are usually treated with heparin for anticoagulation. A serious complication of heparin therapy is heparin-induced thrombocytopenia type II (HIT). Patients with HIT have t...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062506 Heparin-induced thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003439-12 Sponsor Protocol Number: TMP-0916_03 Start Date*: 2018-02-19
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer für Translationale Medizin und Pharmakologie (ITMP)
    Full Title: Safety and efficacy of postoperative i.v. iron substitution with Polyglucoferron compared to Ferric Carboxymaltose and oral iron in patients with diagnosed iron deficiency who develop anaemia pre- ...
    Medical condition: pre-operative iron deficiency in patients with planned elective surgery and pre-/post-operative iron deficiency anamia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004677-20 Sponsor Protocol Number: Gemtax IV Start Date*: 2006-03-17
    Sponsor Name:University of Heidelberg, Klinikum Mannheim, Dep Surgery/Thoracical Oncology
    Full Title: Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stag...
    Medical condition: Lung cancer remains the leading cause of cancer-related death in men and has increased its incidence in women over the past decades (protocol page 9). Data from both meta-analysis and clinical tria...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000452-28 Sponsor Protocol Number: VIPER-OCTA Start Date*: 2014-11-05
    Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank
    Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue – OCTAplas trial
    Medical condition: patients undergoing emergency surgery for thoracic aortic dissections
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10009789 Coagulation factors decreased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019224-31 Sponsor Protocol Number: IGR2009/1593 Start Date*: 2012-06-06
    Sponsor Name:Institut Gustave Roussy
    Full Title: INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS
    Medical condition: untreated advanced stage B-cell NHL or B-AL.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006595 Burkitt's lymphoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067194 Burkitt's leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Ongoing) GB (GB - no longer in EU/EEA) FR (Completed) ES (Temporarily Halted) NL (Completed) HU (Ongoing) IT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001923-53 Sponsor Protocol Number: 7980 Start Date*: 2015-10-07
    Sponsor Name:Rafael Bielza Galindo
    Full Title: Intravenous iron, early functional recovery and delirium in patients atients with hip fracture
    Medical condition: Hip fracture
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022117 - Injury, poisoning and procedural complications 10020100 Hip fracture PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:57:21 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA